The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection

Filovirus proteins for antiviral drug discovery: A structure/function analysis of surface glycoproteins and virus entry

(2016) Baptiste Martin et al.   ANTIVIRAL RESEARCH

PIKfyve Regulates Vacuole Maturation and Nutrient Recovery following Engulfment

(2016) Shefali Krishna et al.   DEVELOPMENTAL CELL

Can you teach old drugs new tricks?

(2016) Nicola Nosengo   NATURE

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

(2016) Travis K. Warren et al.   NATURE

The Glycoproteins of All Filovirus Species Use the Same Host Factors for Entry into Bat and Human Cells but Entry Efficiency Is Species Dependent

(2016) Markus Hoffmann et al.   PLoS One

Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody

(2016) D. Corti et al.   SCIENCE

Structural and molecular basis for Ebola virus neutralization by protective human antibodies

(2016) J. Misasi et al.   SCIENCE

Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak

(2016) Z. A. Bornholdt et al.   SCIENCE

Clomiphene and Its Isomers Block Ebola Virus Particle Entry and Infection with Similar Potency: Potential Therapeutic Implications

(2016) Elizabeth Nelson et al.   Viruses-Basel

Direct Visualization of Ebola Virus Fusion Triggering in the Endocytic Pathway

(2016) Jennifer S. Spence et al.   mBio

Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses

(2016) Julia C. Frei et al.   Scientific Reports

Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site

(2016) Katie A. Howell et al.   Cell Reports

Antibody therapeutics for Ebola virus disease

(2016) Larry Zeitlin et al.   Current Opinion in Virology

Characterization of Yellow Fever Virus Infection of Human and Non-human Primate Antigen Presenting Cells and Their Interaction with CD4+ T Cells

(2016) Yu Cong et al.   PLoS Neglected Tropical Diseases

A Rapid Screening Assay Identifies Monotherapy with Interferon-ß and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus

(2016) Stephen D. S. McCarthy et al.   PLoS Neglected Tropical Diseases

Cysteine Cathepsin Inhibitors as Anti-Ebola Agents

(2016) Wouter A. van der Linden et al.   ACS Infectious Diseases

Discovery of an antibody for pan-ebolavirus therapy

(2016) Wakako Furuyama et al.   Scientific Reports

Structural Basis for Marburg Virus Neutralization by a Cross-Reactive Human Antibody

(2015) Takao Hashiguchi et al.   CELL

Novel Small Molecule Entry Inhibitors of Ebola Virus

(2015) Arnab Basu et al.   JOURNAL OF INFECTIOUS DISEASES

Ebolavirus Glycoprotein Directs Fusion through NPC1 + Endolysosomes

(2015) James A. Simmons et al.   JOURNAL OF VIROLOGY

Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists

(2015) Han Cheng et al.   JOURNAL OF VIROLOGY

Up-regulation of lysosomal TRPML1 channels is essential for lysosomal adaptation to nutrient starvation

(2015) Wuyang Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment

(2015) Yasuteru Sakurai et al.   SCIENCE

A screen of approved drugs and molecular probes identifies therapeutics with anti–Ebola virus activity

(2015) Lisa M. Johansen et al.   Science Translational Medicine

Niemann-Pick C1 Is Essential for Ebolavirus Replication and Pathogenesis In Vivo

(2015) Andrew S. Herbert et al.   mBio

Ebola Virus Entry: A Curious and Complex Series of Events

(2015) Sven Moller-Tank et al.   PLoS Pathogens

Ebolavirus Evolution: Past and Present

(2015) Marc-Antoine de La Vega et al.   PLoS Pathogens

Ebola Virus and Severe Acute Respiratory Syndrome Coronavirus Display Late Cell Entry Kinetics: Evidence that Transport to NPC1+Endolysosomes Is a Rate-Defining Step

(2015) Rebecca M. Mingo et al.   JOURNAL OF VIROLOGY

Convergent regulation of the lysosomal two-pore channel-2 by Mg2+, NAADP, PI(3,5)P2 and multiple protein kinases

(2014) A. Jha et al.   EMBO JOURNAL

A Novel Life Cycle Modeling System for Ebola Virus Shows a Genome Length-Dependent Role of VP24 in Virus Infectivity

(2014) A. Watt et al.   JOURNAL OF VIROLOGY

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells

(2014) Lesley A. Mathews Griner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PIKfyve Inhibition Interferes with Phagosome and Endosome Maturation in Macrophages

(2014) Grace H.E. Kim et al.   TRAFFIC

Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs

(2014) Jennifer Kouznetsova et al.   Emerging Microbes & Infections

Chemical and Structural Aspects of Ebola Virus Entry Inhibitors

(2014) Elisabeth K. Nyakatura et al.   ACS Infectious Diseases

A novel Ebola virus expressing luciferase allows for rapid and quantitative testing of antivirals

(2013) Thomas Hoenen et al.   ANTIVIRAL RESEARCH

PIKfyve, a Class III PI Kinase, Is the Target of the Small Molecular IL-12/IL-23 Inhibitor Apilimod and a Player in Toll-like Receptor Signaling

(2013) Xinming Cai et al.   CHEMISTRY & BIOLOGY

The Quad Pill, a Once-Daily Combination Therapy for HIV Infection

(2013) L. B. Johnson et al.   CLINICAL INFECTIOUS DISEASES

Virus entry at a glance

(2013) Y. Yamauchi et al.   JOURNAL OF CELL SCIENCE

Ebola Virus Exploits a Monocyte Differentiation Program To Promote Its Entry

(2013) O. Martinez et al.   JOURNAL OF VIROLOGY

Multiple Cationic Amphiphiles Induce a Niemann-Pick C Phenotype and Inhibit Ebola Virus Entry and Infection

(2013) Charles J. Shoemaker et al.   PLoS One

A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents

(2013) Peter B. Madrid et al.   PLoS One

FDA-Approved Selective Estrogen Receptor Modulators Inhibit Ebola Virus Infection

(2013) L. M. Johansen et al.   Science Translational Medicine

TPC Proteins Are Phosphoinositide- Activated Sodium-Selective Ion Channels in Endosomes and Lysosomes

(2012) Xiang Wang et al.   CELL

Ebola virus entry requires the host-programmed recognition of an intracellular receptor

(2012) Emily Happy Miller et al.   EMBO JOURNAL

Apilimod Inhibits the Production of IL-12 and IL-23 and Reduces Dendritic Cell Infiltration in Psoriasis

(2012) Yumiko Wada et al.   PLoS One

Brief Report: A phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis

(2011) Sarah Krausz et al.   ARTHRITIS AND RHEUMATISM

Small molecule inhibitors reveal Niemann–Pick C1 is essential for Ebola virus infection

(2011) Marceline Côté et al.   NATURE

Ebola virus entry requires the cholesterol transporter Niemann–Pick C1

(2011) Jan E. Carette et al.   NATURE

Structure and function of the complete internal fusion loop from Ebolavirus glycoprotein 2

(2011) S. M. Gregory et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Designed protein mimics of the Ebola virus glycoprotein GP2 α-helical bundle: Stability and pH effects

(2011) Joseph S. Harrison et al.   PROTEIN SCIENCE

Late-penetrating viruses

(2011) Pierre-Yves Lozach et al.   Current Opinion in Virology

Chemical combinations elucidate pathway interactions and regulation relevant to Hepatitis C replication

(2010) Christopher M Owens et al.   Molecular Systems Biology

Cellular Entry of Ebola Virus Involves Uptake by a Macropinocytosis-Like Mechanism and Subsequent Trafficking through Early and Late Endosomes

(2010) Mohammad F. Saeed et al.   PLoS Pathogens

Ebolavirus Is Internalized into Host Cells via Macropinocytosis in a Viral Glycoprotein-Dependent Manner

(2010) Asuka Nanbo et al.   PLoS Pathogens

YM201636, an inhibitor of retroviral budding and PIKfyve-catalyzed PtdIns(3,5)P2 synthesis, halts glucose entry by insulin in adipocytes

(2009) Ognian C. Ikonomov et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Phosphatidylinositol 3,5-bisphosphate and Fab1p/PIKfyve underPPIn endo-lysosome function

(2009) Stephen K. Dove et al.   BIOCHEMICAL JOURNAL

Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohnʼs disease

(2009) Bruce E. Sands et al.   INFLAMMATORY BOWEL DISEASES

NAADP mobilizes calcium from acidic organelles through two-pore channels

(2009) Peter J. Calcraft et al.   NATURE

Synergistic drug combinations tend to improve therapeutically relevant selectivity

(2009) Joseph Lehár et al.   NATURE BIOTECHNOLOGY

PIKfyve: Partners, significance, debates and paradoxes

(2008) A SHISHEVA   CELL BIOLOGY INTERNATIONAL

A selective PIKfyve inhibitor blocks PtdIns(3,5)P2 production and disrupts endomembrane transport and retroviral budding

(2008) Harold B J Jefferies et al.   EMBO REPORTS